A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer

Show simple item record

dc.contributor.author Salminen, Liina
dc.contributor.author Nadeem, Nimrah
dc.contributor.author Jain, Shruti
dc.contributor.author Grènman, Seija
dc.contributor.author Carpén, Olli
dc.contributor.author Hietanen, Sakari
dc.contributor.author Oksa, Sinikka
dc.contributor.author Lamminmäki, Urpo
dc.contributor.author Pettersson, Kim
dc.contributor.author Gidwani, Kamlesh
dc.contributor.author Huhtinen, Kaisa
dc.contributor.author Hynninen, Johanna
dc.date.accessioned 2020-04-27T12:56:01Z
dc.date.available 2020-04-27T12:56:01Z
dc.date.issued 2020-03
dc.identifier.citation Salminen , L , Nadeem , N , Jain , S , Grènman , S , Carpén , O , Hietanen , S , Oksa , S , Lamminmäki , U , Pettersson , K , Gidwani , K , Huhtinen , K & Hynninen , J 2020 , ' A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer ' , Gynecologic Oncology , vol. 156 , no. 3 , pp. 689-694 . https://doi.org/10.1016/j.ygyno.2019.12.025
dc.identifier.other PURE: 132986962
dc.identifier.other PURE UUID: f262d28c-7d36-4448-bccb-9824f03a8810
dc.identifier.other RIS: urn:24C62292DB94A9C44C01B522C17446C6
dc.identifier.other WOS: 000518876200027
dc.identifier.uri http://hdl.handle.net/10138/314435
dc.description.abstract Objective. Cancer antigen 125 (CM 25) is generally considered the gold standard of biomarkers in the diagnosis and monitoring of high grade serous ovarian carcinoma (HGSC). We recently reported, that two CM 25 glycoforms (CA125-STn and CA125-MGL) have a high specificity to HGSC and further hypothesized, that these cancer specific glycoforms are feasible candidates as biomarkers in HGSC treatment and follow up. Methods. Our cohort consisted of 122 patients diagnosed with HGSC. Serum samples were collected longitudinally at the time of diagnosis, during treatment and follow up. Serum levels of CA125, CM 25-STn and CA125MGL were determined and compared or correlated with different end points (tumor load assessed intraoperatively, residual disease, treatment response, progression free survival). Results. Serum CA125-STn levels at diagnosis differentiated patients with low tumor load and high tumor load (p = 0,030), indicating a favorable detection of tumor volume. Similarly, the CA125-STn levels at diagnosis were significantly lower in patients with subsequent complete cytoreduction than in patients with suboptimal cytoreduction (p = 0,025). Conventional CA125 did not differentiate these patients (p = 0,363 and p = 0,154). The CA125-STn nadir value predicted the progression free survival of patients. The detection of disease relapse was improved with CA125-STn, which presented higher fold increase in 80,0% of patients and earlier increase in 37,0% of patients. Conclusions. CA125-STn showed promise as a useful biomarker in the monitoring and follow up of patients with HGSC utilizing a robust and affordable technique. Our findings are topical as a suitable indicator of tumor load facilitates patient selection in an era of new targeted therapies. (C) 2019 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/). en
dc.format.extent 6
dc.language.iso eng
dc.relation.ispartof Gynecologic Oncology
dc.rights cc_by
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject 3122 Cancers
dc.subject Ovarian cancer
dc.subject High grade serous ovarian carcinoma
dc.subject CA125
dc.subject Glycoform
dc.subject SURVIVAL
dc.subject RECIST
dc.subject LEVEL
dc.subject PROGRESSION
dc.subject 3123 Gynaecology and paediatrics
dc.title A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer en
dc.type Article
dc.contributor.organization HUSLAB
dc.contributor.organization Precision Cancer Pathology
dc.contributor.organization Department of Pathology
dc.contributor.organization Helsinki University Hospital Area
dc.contributor.organization University of Helsinki
dc.contributor.organization Research Programs Unit
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1016/j.ygyno.2019.12.025
dc.relation.issn 0090-8258
dc.rights.accesslevel openAccess
dc.type.version publishedVersion
dc.type.version draft

Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S0090825819318463_main.pdf 609.6Kb PDF View/Open
A_longitudinal_ ... _serous_ovarian_cancer.pdf 646.7Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record